Navigation Links
Evolution of human genome's 'guardian' gives people unique protections from DNA damage
Date:1/16/2008

CINCINNATI Human evolution has created enhancements in key genes connected to the p53 regulatory network the so-called guardian of the genome by creating additional safeguards in human genes to boost the networks ability to guard against DNA damage that could cause cancer or a variety of genetic diseases, an international team of scientists led by Cincinnati Childrens Hospital Medical Center writes in the Jan. 22 Proceedings of the National Academy of Sciences. Because genetically engineered mouse models are increasingly powerful tools in understanding the risks and mechanisms of human diseases and rodents do not have the same evolution-based safeguards in p53 function as humans the study also underscores the need for additional considerations in the interpretation of research using rodent models.

Our findings are especially important because rodents are often used as model organisms to investigate the genetic origins of diseases that affect humans, such as cancer investigators evaluating the impact of DNA-damaging agents, said Anil Jegga, DVM, a researcher in the Division of Biomedical Informatics at Cincinnati Childrens. Rodent models remain important to our understanding of disease processes, although our study suggests the need to address experimentally the differences in p53 regulatory pathways between humans and rodent models.

In the study, Jegga and his colleagues used comparative functional genomics to look systematically at small DNA sequences associated with the promoters, or enhancers, of specific genes that carry out orders from p53. These promoter elements act like antennae responding to activated p53 by boosting target gene expression and function inside a cells nucleus. By comparing these response elements across nearly 50 different binding sites of genes in the p53 network, and looking specifically at genes that repair DNA damage in 14 species (from zebra fish to humans), researchers were able to reveal critical evoluti
'/>"/>

Contact: Nick Miller
513-803-6035
Cincinnati Children's Hospital Medical Center
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Local Oncology Group Leads Online Effort to Revolutionize Cancer Care
2. Join the Vitamin D Revolution: How to Get 30 Minutes of Daily Sunshine for Optimal Health
3. VIDEO from Medialink and Revolution Health: RevolutionHealth.com Launches Resolutions 2.0
4. UCLA Program Aims to Revolutionize Kidney Transplants
5. Prescription for an electronic revolution?
6. Adapting to pregnancy played key role in human evolution, study shows
7. Evolution Tips the Balance in Moms Favor
8. Informed Medical Communications Sells Consumer Internet Division to Revolution Health
9. Chinas Anti-Aging Revolution
10. New Low-Impact Cosmetic Surgery Treatments Revolutionizing Industry
11. ILC Dover Launches Revolutionary ArmorFlex (R) Pharmaceutical Product Contact Film
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2008).... Researchers at the University of Michigan Compr...ers that indicate which patients are more likely t...nsils. , Most notably, they found that cancers ...st responsive to current chemotherapy and radiatio...s of a certain growth factor receptor are the leas...
(Date:5/12/2008)...., May 12 /PRNewswire/ -- Keck Graduate Institute ...ncement ceremony will feature,the graduation of KG...ic,Tan, and the unveiling of KGI,s first donated a... achievement in becoming the,first graduate of our...nior,vice president for academic affairs, dean of ...
(Date:5/12/2008)... NASDAQ: CRME TSX: COM, VANCOUVER, May 12 /...DAQ: CRME / TSX: COM) today announced that it will... 2008 on the afternoon of Tuesday, May 13,2008. C...t at 4:30pm,Eastern (1:30pm Pacific) on that day t...call, please dial 416-641-6117 or,866-299-6655. Th...
(Date:5/12/2008)... Webcast Featuring Synchronized Slides at 5pm Toda... -- NxStage Medical, Inc.,(Nasdaq: NXTM ), a lead...today announced its financial results for the firs... first quarter of 2008 were $31.0 million, compare... $29.9 million in the fourth,quarter of 2007. Reve...
Breaking Medicine News(10 mins):Health News:HPV linked to better survival in tonsil, tongue cancer, U-M study finds 2Health News:HPV linked to better survival in tonsil, tongue cancer, U-M study finds 3Health News:KGI 2008 Commencement Features First PhD Graduate, Biotech Painting 2Health News:Cardiome To Release 2008 First Quarter Results 2Health News:Cardiome To Release 2008 First Quarter Results 3Health News:Cardiome To Release 2008 First Quarter Results 4Health News:NxStage Medical Reports First Quarter 2008 Results 2Health News:NxStage Medical Reports First Quarter 2008 Results 3Health News:NxStage Medical Reports First Quarter 2008 Results 4Health News:NxStage Medical Reports First Quarter 2008 Results 5Health News:NxStage Medical Reports First Quarter 2008 Results 6Health News:NxStage Medical Reports First Quarter 2008 Results 7Health News:NxStage Medical Reports First Quarter 2008 Results 8Health News:NxStage Medical Reports First Quarter 2008 Results 9Health News:NxStage Medical Reports First Quarter 2008 Results 10Health News:NxStage Medical Reports First Quarter 2008 Results 11
... the University of Missouri-Columbia; is of the vi...ld be a good source for cattle feed. In his stud... at the College of Agriculture, is examining the e...n as cattle feed. Through November, Kerley will ...
...uths to learn meditation from Indian spiritual gur...visit to the war-hit country Thursday with a trip ...of Living Foundation, Iraqi Youth Minister Jasin M...hree youths from each province of Iraq to Bangalor...
...hrax in Orissa's tribal dominated Koraput district... the last two days, health officials said Friday.... 35, of Padiguda village under Semliguda block in ... Bhubaneswar, fell to the disease reportedly after...
...m Friday urge the nation's doctors to work for rur...t-Graduate Institute of Medical Sciences in Rohtak...ties available for village India. If each doctor ...t at least 20 rural patients a year, the president...
Other Medicine News:Health News:Study Finds Glycerin to Be a Good Source for Cattle Feed 2Health News:Art of Living Foundation to Train Iraqi Youths 2
(Date:5/12/2008)...NTA, May 12 /- GeoVax Labs,...d HIV/AIDS vaccine development,company, announced ...n,stock purchase agreement with Fusion Capital Fun..., The Company may sell up to $10 million of its c...er a 25-month period after the Securities and,Exch...
(Date:5/12/2008)...ides the Optimal Combination of Scaffolding, Deliv...bility, TEL AVIV, Israel, May 12 /- ...CE Mark for its Presillion(TM) CoCr Coronary Stent...ions with a technologically,innovative flexible cl... the superb scaffolding the unprecedented,balance ...
(Date:5/12/2008)...ADELPHIA, May 12 /PRNewswire-USNewswire/ -- GlaxoS...International Group (BIG), a leading,academic brea...groups, the,Spanish Breast Cancer Cooperative Grou...hase III study that will examine the role of TYKER...ALTTO (Neoadjuvant Lapatinib and/or,Trastuzumab Tr...
(Date:5/9/2008)..., Fla., May 9 /PRNewswire-USNewswire/ -- Osteoarth...ndition that affects almost 50,million people in t...,cartilage in bone joints. The novel investigation...oral analgesic, provided significant relief,for pa...treated with,placebo, and with fewer gastrointesti...
Breaking Medicine Technology:GeoVax Secures $10 Million Financing Commitment 2GeoVax Secures $10 Million Financing Commitment 3Medinol Receives CE Mark for Presillion(TM) Cobalt Chromium Coronary Stent on Rx System, an Advanced Evolution of the NIR(R) Family of Stents 2TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 2TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 3TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 4TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 5TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 6TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 7Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 2Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 3Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 4Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 5Friends of Warren Zevon To Play at Maverick Saloon Raising Awareness of Asbestos Cancer Mesothelioma 5200 1Friends of Warren Zevon To Play at Maverick Saloon Raising Awareness of Asbestos Cancer Mesothelioma 5200 2West Pharmaceutical Services Announces Third Quarter 2007 Results 5198 1West Pharmaceutical Services Announces Third Quarter 2007 Results 5198 2West Pharmaceutical Services Announces Third Quarter 2007 Results 5198 3West Pharmaceutical Services Announces Third Quarter 2007 Results 5198 4West Pharmaceutical Services Announces Third Quarter 2007 Results 5198 5West Pharmaceutical Services Announces Third Quarter 2007 Results 5198 6West Pharmaceutical Services Announces Third Quarter 2007 Results 5198 7West Pharmaceutical Services Announces Third Quarter 2007 Results 5198 8West Pharmaceutical Services Announces Third Quarter 2007 Results 5198 9West Pharmaceutical Services Announces Third Quarter 2007 Results 5198 10West Pharmaceutical Services Announces Third Quarter 2007 Results 5198 11West Pharmaceutical Services Announces Third Quarter 2007 Results 5198 12West Pharmaceutical Services Announces Third Quarter 2007 Results 5198 13West Pharmaceutical Services Announces Third Quarter 2007 Results 5198 14West Pharmaceutical Services Announces Third Quarter 2007 Results 5198 15West Pharmaceutical Services Announces Third Quarter 2007 Results 5198 16West Pharmaceutical Services Announces Third Quarter 2007 Results 5198 17United Therapeutics Reports Third Quarter 2007 Financial Results 1642 1United Therapeutics Reports Third Quarter 2007 Financial Results 1642 2United Therapeutics Reports Third Quarter 2007 Financial Results 1642 3United Therapeutics Reports Third Quarter 2007 Financial Results 1642 4United Therapeutics Reports Third Quarter 2007 Financial Results 1642 5United Therapeutics Reports Third Quarter 2007 Financial Results 1642 6United Therapeutics Reports Third Quarter 2007 Financial Results 1642 7United Therapeutics Reports Third Quarter 2007 Financial Results 1642 8United Therapeutics Reports Third Quarter 2007 Financial Results 1642 9Neurocrine Biosciences and Dainippon Sumitomo Pharma 28DSP 29 Announce Agreement to Develop and Commercialize Indiplon in Japan 1640 1Neurocrine Biosciences and Dainippon Sumitomo Pharma 28DSP 29 Announce Agreement to Develop and Commercialize Indiplon in Japan 1640 2Neurocrine Biosciences and Dainippon Sumitomo Pharma 28DSP 29 Announce Agreement to Develop and Commercialize Indiplon in Japan 1640 3
The design and concept of the Alpina knee allows the choice of implanting a PCL retaining or a posterior stabilized prosthesis intraoperatively, right up until the definitive implants are to be put i
Tibial distractor
...werSuite™ holmium laser combines excellent c...ecise, virtually bloodless procedures. It is also ...l bladder stones of all compositions, making it an...er light is transmitted through flexible fibers, i...
...werSuite™ holmium laser combines excellent c...ecise, virtually bloodless procedures. It is also ...l bladder stones of all compositions, making it an...er light is transmitted through flexible fibers, i...
Medicine Products: